This test measures the presence of leukaemia at a molecular level rather than at a cellular level. It quantifies a minimal residual disease (MRD) level for patients.
Biomarkers are attached to the leukaemia cells. These remaining leukaemia cells are measured using molecular techniques. Commonly, flow cytometry determines the small level of leukaemia cells still remaining in patients’ blood or bone marrows.
Haematologists use patients’ MRD status to assess therapeutic response and guide treatment decisions.